Search the Newsreel

S&CO Inc. Takes Position in Astrazeneca Plc $AZN

S&CO Inc. has acquired a new stake in AstraZeneca Plc, purchasing 37,990 shares valued at approximately $7.1 million during the second quarter. Institutional investors now collectively own 20.35% of AstraZeneca's stock. Analysts maintain a "Moderate Buy" rating for AstraZeneca, with an average price target …

AstraZeneca stock trades around $157 as Q2 2026 EPS beats expectations

AstraZeneca slips Friday, underperforms market

AstraZeneca PLC (AZN) shares fell 2.12% to £114.60 on Friday, underperforming the broader market as the FTSE 100 Index also declined. The company's stock closed significantly below its 52-week high, which was achieved earlier in the year.

AstraZeneca stock holds near $157 after earnings beat

Is the Reported $400 Billion AstraZeneca-Bristol Myers Squibb Megamerger a Slam Dunk -- or a Disaster Waiting to Happen?

Key Points Earlier this month, AstraZeneca and Bristol Myers Squibb became the subject of merger rumors. Investors reacted negatively to the rumors, even if on paper such a deal would create an oncology-focused big pharma powerhouse worth around $400 billion. Considering regulatory uncertainty and …

Wealthcare Advisory Partners LLC Purchases Shares of 12,112 Astrazeneca Plc $AZN

Wealthcare Advisory Partners LLC acquired 12,112 shares of AstraZeneca Plc, valued at approximately $2.3 million, in the second quarter. This move is part of a broader trend of institutional investors increasing their holdings in the pharmaceutical company, which now has 20.35% institutional ownership. AstraZeneca …

AstraZeneca Stock And 2 Cash Flow Picks Trading Below Fair Value

AstraZeneca slips Wednesday, underperforms market

AstraZeneca PLC (AZN) shares fell 1.20% to £117.02 on Wednesday, underperforming the broader market as the FTSE 100 Index (UKX) also dropped. The company's stock closed 25.62% below its 52-week high.

How AstraZeneca’s $400bn deal unravelled

One Broadway deal to start: Hollywood mogul Ari Emanuel has struck a roughly £4.5bn deal to buy the theatre group behind West End venues including the Lyceum and the Savoy in a major bet that strong demand for live events is here to stay. …

AstraZeneca PLC (AZN) News, Articles, Events & Latest Updates

This article provides a compilation of recent news and updates concerning AstraZeneca PLC (AZN). Key topics include options market movements, hedge fund bullishness, and reports of potential acquisition talks with Bristol Myers Squibb. It also covers related pharmaceutical news such as Merck's performance and …

AstraZeneca PLC (AZN) vs. Bristol-Myers Squibb Company (BMY): Wall Street Doesn’t Buy This Merger Talk

AstraZeneca PLC (NYSE:AZN) shares closed down as much as 9% on Monday, the stock's biggest one-day drop since 2020, after reports that it held merger talks with U.S. rival Bristol-Myers Squibb Company (NYSE:BMY). A combined company would be worth close to $400 billion, the …

Do Options Traders Know Something About AstraZeneca Stock We Don't?

Investors in AstraZeneca PLC AZN need to pay close attention to the stock based on moves in the options market lately. That is because the Jan. 15, 2027 $115.00 Call had some of the highest implied volatility of all equity options today. What is …

Hedge Funds are Bullish on AstraZeneca PLC (AZN)

AstraZeneca PLC (NYSE:AZN) topped second-quarter profit expectations, with core earnings per share of $2.63 versus the $2.48 analysts expected. The firm reiterated its target of $80 billion in annual revenue by 2030. However, the quarter also brought fresh pipeline trouble: its rare disease drug …

AstraZeneca stock outlook: Seller pressure limits upside for AZN

VELA LARGE CAP PLUS FUND's AstraZeneca PLC(AZN) Holding History

This article details VELA LARGE CAP PLUS FUND's holding history for AstraZeneca PLC (AZN). As of March 31, 2026, the fund held 4,854 shares of AZN, valued at $957,310, constituting 1.64% of its portfolio. The initial purchase occurred in Q1 2026 at an average …

Can AstraZeneca (AZN) Reach Its $80 Billion Revenue Goal Despite Clinical Setbacks?

It was reported on July 27 that AstraZeneca PLC (NASDAQ:AZN) shares outperformed in European trading after the company reported second-quarter earnings that beat Wall Street expectations and reiterated its full-year 2026 guidance. Core earnings per share (EPS) jumped 18% on a constant exchange rate …

AstraZeneca PLC (AZN) Stock Analysis: Unveiling a 32% Potential Upside Amid Strong Buy Ratings

Astrazeneca Plc $AZN Shares Sold by FNY Investment Advisers LLC

FNY Investment Advisers LLC significantly reduced its stake in AstraZeneca Plc by 97.2% in Q2 2026, selling 7,050 shares and retaining 200. This comes despite AstraZeneca beating EPS estimates with $2.63, though its revenue of $15.38 billion slightly missed forecasts. The stock currently holds …

AstraZeneca (LSE:AZN) Signs Two Cancer Diagnostics Deals To Widen Patient Access

Make better investment decisions with Simply Wall St's easy, visual tools that give you a competitive edge. SOPHiA GENETICS and AstraZeneca (LSE:AZN) have entered a global partnership to develop and launch two decentralized companion diagnostics in precision oncology. The multi-year collaboration focuses on clinical …

Parallel Advisors LLC Purchases New Position in Astrazeneca Plc $AZN

Parallel Advisors LLC has acquired a new position in AstraZeneca Plc, purchasing 8,718 shares valued at approximately $1.72 million in the first quarter. This comes as institutional investors collectively own 20.35% of AstraZeneca, and analysts maintain a "Moderate Buy" consensus rating with an average …

161,624 Shares in Astrazeneca Plc $AZN Acquired by Professional Advisory Services Inc.

Professional Advisory Services Inc. recently acquired 161,624 shares of AstraZeneca Plc (NYSE:AZN) for approximately $30.2 million, making it their seventh-largest holding. AstraZeneca reported strong quarterly earnings, beating EPS estimates, and analysts maintain a "Moderate Buy" rating for the stock. The company's financial performance and …

Jefferies Reaffirms Their Buy Rating on AstraZeneca (AZN)

AstraZeneca PLC Stock 12‑Month Price Target Raised to $216.47, Implies 34% Upside

AstraZeneca PLC's average 12-month price target has been increased to $216.47, up from $215.03, according to 26 analysts. This updated target suggests a potential upside of approximately 34% based on the August 6 closing price. The consensus rating from 31 analysts remains a "Buy," …

Noticias de acciones de AstraZeneca PLC (AZN)

AstraZeneca (LSE:AZN) Merger Talk Fades, Is The Stock Undervalued?

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. AstraZeneca (LSE:AZN) is back in focus after a senior source told Reuters that there are no ongoing merger discussions with Bristol Myers Squibb, reversing earlier …

How the FTSE became a ‘departure lounge’ for British companies

On holiday in Devon this summer, Charles Hall felt a familiar sinking feeling. The most senior analyst at City stockbroker Peel Hunt had just read that AstraZeneca held talks with US pharmaceutical giant Bristol Myers Squibb about a potential merger. It reignited concerns that …

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN

Pomerantz LLP is investigating potential claims on behalf of investors of AstraZeneca PLC (NYSE: AZN) following a significant drop in its stock price. This investigation comes after AstraZeneca disclosed that its late-stage Phase-3 CARDIO-TTransform trial for Wainua, an amyloid cardiomyopathy treatment, failed to meet …

AstraZeneca Stock Leads 3 Cash Flow Picks Worth Watching In Europe

Deal or No Deal, AstraZeneca Stock Is a Bargain

AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are down over 10% for the year and …

AZN rebounds after report dismisses AstraZeneca-Bristol Myers merger speculation

Astra Zeneca logo on building ©Adobe Stock Images AstraZeneca (NASDAQ:AZN) shares climbed around 6% on Wednesday after Reuters reported that there are "no discussions" between the company and Bristol Myers Squibb (NYSE:BMY) regarding a potential merger, contradicting recent speculation that had unsettled investors. The …

Exclusive-'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

By Maggie Fick and Sabrina Valle Aug 5 (Reuters) - There are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb over a ‌potential deal, a senior source close to the matter told ‌Reuters on Wednesday, quashing the prospect of a mooted mega merger …

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls

Best Buy downgraded, Bristol Myers upgraded: Wall Street's top analyst calls The most talked about and market moving research calls around Wall Street are now in one place. Here are today's research calls that investors need to know, as compiled by The Fly. Top …

AZN spikes 6% after report it denies AstraZeneca-BMS merger talks

Investing.com - AstraZeneca shares surged approximately 6% on Wednesday after a senior source told Reuters there are "no discussions" between AstraZeneca and Bristol Myers Squibb over a potential deal, flatly quashing reports of a merger that would have created a pharmaceutical giant worth nearly …